News

Karyopharm Therapeutics is set to present novel clinical data on its lead product candidate selinexor, an oral selective inhibitor of nuclear export compound that is being developed for a variety of advanced hematologic and solid tumors. The data, to be presented at the upcoming American Society of Hematology (ASH)…

MorphoSys, the creator of HuCAL (Human Combinatorial Antibody Library), will give two oral and one poster presentation on the company’s proprietary antibody hemato-oncological programs, MOR208 and MOR202, at the upcoming 58th American Society of Hematology Annual Meeting (ASH 2016) Dec. 3-6 in San Diego, Calif.. “We are pleased that updated…

Genentech will present results on several approved or investigational therapies for blood cancers, including lymphoma and myeloma, in the upcoming 58th American Society of Hematology (ASH) Annual Meeting in San Diego, Dec. 3-6. Results, which include data for Gazyva (obinutuzumab), Rituxan (rituximab), Venclexta (venetoclax) and emicizumab, will be…

Adaptimmune Therapeutics and Merck have agreed to begin a clinical trial next year assess the safety and efficacy of combining the anti-PD-1 inhibitor Keytruda (pembrolizumab) with Adaptimmune’s NY-ESO Spear T-cell therapy in multiple myeloma patients. The agreement states that the trial will be sponsored by Adaptimmune, and includes a provision…

Patients treated for multiple myeloma at facilities that see a higher number of multiple myeloma patients annually had better outcomes compared to patients who were treated at lower-volume facilities, researchers at the Mayo Clinic found. The research study, “Association Between Treatment Facility Volume and Mortality of Patients With Multiple Myeloma,” was…

Longer duration of maintenance therapy with Revlimid (lenalidomide) after autologous hematopoietic stem cell transplantation (HSCT) prolongs survival for multiple myeloma patients without increasing their risk of developing other primary cancers, researchers found. The findings come from the retrospective study “Prolonged survival with a longer duration…

Inhibiting a key protein in the tumor microenvironment using Noxxon’s experimental agent NOX-A12 may enhance the clinical activity of immunotherapies that boost T-cells or natural killer cells, according to preclinical data presented at the European Society for Medical Oncology (ESMO) 2016 Congress in Copenhagen. NOX-A12 (olaptesed pegol) is currently in…

Amgen announced that its RANKL inhibitor, Xgeva (denosumab) met its primary endpoint in a  Phase 3 trial as a potential treatment for bone complications in multiple myeloma — that of non-inferior results, compared to zoledronic acid, in delaying the time to a first, on-study skeletal-related event in newly diagnosed patients. But the trial failed to…

A three-drug therapy combination consisting of Darzalex (daratumumab) with Revlimid (lenalidomide) and Decadron (dexamethasone) shows real potential in increasing survival in patients with relapsed or refractory multiple myeloma, according to an interim analysis of a Phase 3 trial. But the data in the study, “Daratumumab,…

Understanding how multiple myeloma develops and responds to therapies may be easier using a new mouse model developed at Yale University School of Medicine. The model supports the growth of cells derived from patients with multiple myeloma or the disease’s precursor states. The study, “Microenvironment-Dependent Growth Of Preneoplastic And Malignant Plasma…